Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Flinders Health and Medical Research Institute, Flinders University, Australia.
PLoS Negl Trop Dis. 2020 Dec 8;14(12):e0008936. doi: 10.1371/journal.pntd.0008936. eCollection 2020 Dec.
Snakebite is a neglected tropical disease with significant morbidity and mortality. Thrombotic microangiopathy (TMA) is an important but poorly understood complication of snakebite associated with acute kidney injury (AKI). Numerous treatments have been attempted based on limited evidence. We conducted a systematic review of TMA following snakebite using a pre-determined case definition of blood film red cell schistocytes or histologically diagnosed TMA. The search strategy included major electronic databases and grey literature. We present a descriptive synthesis for the outcomes of AKI, dialysis free survival (DFS), other end-organ damage, overall survival, and interventions with antivenom and therapeutic plasmapheresis (TPE). This study was prospectively registered with PROSPERO (CRD42019121436). Seventy-two studies reporting 351 cases were included, predominantly small observational studies. Heterogeneity for study selection, design, reporting and outcomes were observed. The commonest envenoming species were hump-nosed vipers (Hypnale spp.), Russell's viper (Daboia russelii) and Australian brown snakes (Pseudechis spp.). The prevalence of TMA was at least 5.4% in proven and probable Hypnale bites, and 10-15% of Australian elapid envenomings, AKI occurred in 94% (293/312) of TMA cases, excluding case reports. The majority of cases with AKI required dialysis. Included prospective and retrospective cohort studies reporting interventions and renal outcomes showed no evidence for benefit from antivenom or TPE with respect to DFS in dialysis dependant AKI. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) assessment for quality of accumulated evidence for interventions was low. The major complication of TMA following snakebite is AKI. AKI improves in most cases. We found no evidence to support benefit from antivenom in snakebite associated TMA, but antivenom remains the standard of care for snake envenoming. There was no evidence for benefit of TPE in snakebite associated TMA, so TPE cannot be recommended. The quality of accumulated evidence was low, highlighting a need for high quality larger studies.
蛇伤是一种被忽视的热带病,具有较高的发病率和死亡率。血栓性微血管病(TMA)是一种重要但尚未被充分了解的蛇伤相关并发症,与急性肾损伤(AKI)有关。基于有限的证据,已经尝试了许多治疗方法。我们使用血液涂片红细胞裂片或组织学诊断的 TMA 的预先确定的病例定义,对蛇伤后的 TMA 进行了系统评价。搜索策略包括主要的电子数据库和灰色文献。我们为 AKI、无透析生存(DFS)、其他终末器官损伤、总生存以及使用抗蛇毒血清和治疗性血浆置换(TPE)的干预措施的结果提供了描述性综合。这项研究在 PROSPERO(CRD42019121436)上进行了前瞻性注册。有 72 项研究报告了 351 例病例,主要是小型观察性研究。研究选择、设计、报告和结果存在异质性。最常见的中毒物种是驼峰鼻蝮(Hypnale spp.)、圆斑蝰(Daboia russelii)和澳大利亚棕色蛇(Pseudechis spp.)。在已证实和可能的 Hypnale 咬伤中,TMA 的患病率至少为 5.4%,在澳大利亚的 elapid 咬伤中为 10-15%,AKI 发生在 312 例 TMA 病例中的 94%(293/312),不包括病例报告。大多数 AKI 患者需要透析。包括干预和肾脏结局的前瞻性和回顾性队列研究报告没有证据表明抗蛇毒血清或 TPE 对依赖透析的 AKI 的 DFS 有获益。对于干预措施的累积证据质量的分级评估、评估、制定和评价(GRADE)评估为低。蛇伤后 TMA 的主要并发症是 AKI。大多数情况下 AKI 会改善。我们没有发现抗蛇毒血清在蛇伤相关 TMA 中有获益的证据,但抗蛇毒血清仍然是蛇伤的标准治疗方法。在蛇伤相关 TMA 中,TPE 没有获益的证据,因此不能推荐 TPE。累积证据的质量较低,这突显了需要进行高质量的大型研究。